EUVIMEDDescoperă EUVIMED
Crossref

Reduced dosing versus full dosing valganciclovir for prophylaxis of cytomegalovirus in high‐risk abdominal transplant recipients

Maura L Kreiser iD, Robert Dupuis, Kristen R Szempruch iD, Laura M Chargualaf

Clinical Transplantation · 2023

DOI: 10.1111/ctr.15041 ↗

At a glance

Journal article in Clinical Transplantation, 2023. Written by Maura L Kreiser and 3 co-authors. Institution: Department of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, U…. Major MEDLINE topics: Cytomegalovirus Infections, Neutropenia. Cited 2 times so far (Crossref); 22 references.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Background

Cytomegalovirus (CMV) is a common infection in abdominal transplant recipients (ATR). Prevention of CMV in the highest risk population (CMV IgG donor+/recipient‐) is critical as CMV is associated with negative outcomes. Guideline recommended prophylactic valganciclovir dosing is 900 mg daily for 6 months in this population. However, reduced dosing strategies are utilized in practice.

Methods

This single center, retrospective study in adult ATR compared full valganciclovir prophylactic dosing (900 mg daily for 6 months) to reduced dosing (900 mg daily for 3 months, then 450 mg daily for 3 months). The primary endpoint was incidence of CMV infection with viral load >1000 IU/mL. Secondary endpoints included incidence of CMV infection with viral load 200–1000 IU/mL, neutropenia, and leukopenia.

Results

Incidence of CMV infection with viral load >1000 IU/mL (29% vs. 27%, p = 1) or CMV infection with viral load 200‐1000 IU/mL (6% vs. 12%, p = .421) did not differ significantly between 68 ATR in reduced and full dosing groups, as well as incidence of leukopenia (94% vs. 97%, p = 1) and neutropenia (77% vs. 70%, p = .586).

Conclusions

There was no difference in the incidence of CMV infection, neutropenia, or leukopenia of the two dosing regimens, although time to CMV diagnosis was different.

Subjects

MeSH terms (MEDLINE)

Cytomegalovirus InfectionsNeutropeniaAdultHumansValganciclovirCytomegalovirusAntiviral AgentsGanciclovirRetrospective StudiesTransplant Recipients

Author keywords

cytomegaloviruskidney transplantprophylaxisvalganciclovir

Substances

ValganciclovirAntiviral AgentsGanciclovir

Authors and institutions

  • Department of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
  • Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina, USA.

ORCID profiles: Maura L Kreiser, Kristen R Szempruch

Cite

APA

Kreiser, M. L., Dupuis, R., Szempruch, K. R., & Chargualaf, L. M. (2023). Reduced dosing versus full dosing valganciclovir for prophylaxis of cytomegalovirus in high‐risk abdominal transplant recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.15041

Vancouver

Kreiser ML, Dupuis R, Szempruch KR, Chargualaf LM. Reduced dosing versus full dosing valganciclovir for prophylaxis of cytomegalovirus in high‐risk abdominal transplant recipients. Clinical Transplantation. 2023. doi:10.1111/ctr.15041

BibTeX
@article{Kreiser2023,
  author = {Kreiser, Maura L and Dupuis, Robert and Szempruch, Kristen R and Chargualaf, Laura M},
  title = {Reduced dosing versus full dosing valganciclovir for prophylaxis of cytomegalovirus in high‐risk abdominal transplant recipients},
  journal = {Clinical Transplantation},
  year = {2023},
  doi = {10.1111/ctr.15041}
}
Start for free →